Atossa Therapeutics Reports Q1 2025 Financial Results

Atossa Therapeutics, Inc. ( (ATOS) ) has released its Q1 earnings. Here is a breakdown of the information Atossa Therapeutics, Inc. presented to its investors.

Atossa Therapeutics, Inc. is a biotechnology company focused on developing innovative medicines for breast cancer and other breast conditions, operating primarily in the oncology sector. In its latest quarterly earnings report, Atossa Therapeutics reported a net loss of $6.7 million for the first quarter of 2025, compared to a net loss of $5.9 million in the same period last year. The company’s cash and cash equivalents decreased to $65.1 million from $71.1 million at the end of 2024, reflecting its ongoing investment in research and development. Key financial metrics highlighted in the report include total operating expenses of $7.4 million, driven by research and development costs of $4.2 million and general administrative expenses of $3.3 million. Despite the losses, Atossa Therapeutics maintains a strong cash position to support its operations for at least the next year. Looking ahead, the company plans to continue its focus on developing its proprietary (Z)-endoxifen for breast cancer treatment, while seeking additional funding through various channels to support its long-term business strategy.